Mutations only arise *after* treatment. Same as with BCR ABL drugs. They may get a few Pfizer failures in their first cohorts who would be nice to show efficacy with. I'm sure they will determine which mutations those patients have.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.